Protein Kinase Inhibitors: Insights into Drug Design from Structure

Science

Volumn 303, Issue 5665, 2004, Pages 1800-1805

  Noble, Martin E M ^a   Endicott, Jane A ^a   Johnson, Louise N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; DRUG PRODUCTS; ENZYMES; INFORMATION ANALYSIS; TUMORS;

INFLAMMATION; THERAPEUTIC AGENTS;

ENZYME INHIBITION;

1 [5 TERT BUTYL 2 (4 TOLYL) 2H PYRAZOL 3 YL] 3 [4 (2 MORPHOLIN 4 YLETHOXY)NAPHTHALEN 1 YL]UREA; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; 6 (2,6 DICHLOROPHENYL) 8 METHYL 2 (3 METHYLTHIOANILINO) 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 7 HYDROXYSTAUROSPORINE; BEVACIZUMAB; CETUXIMAB; DORAMAPIMOD; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FASUDIL; FIBROBLAST GROWTH FACTOR RECEPTOR; GEFITINIB; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; H 1152P; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; PACLITAXEL; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; SEMAXANIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE; VATALANIB; VX 702; WORTMANNIN;

PHARMACEUTICAL INDUSTRY;

BRAIN VASOSPASM; CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CROHN DISEASE; DRUG DESIGN; DRUG STRUCTURE; ENZYME INHIBITION; GASTROINTESTINAL TUMOR; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; BINDING SITES; CATALYTIC DOMAIN; CLINICAL TRIALS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642323740     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1095920     Document Type: Review

References (72)

1. G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, Science 298, 1912 (2002).
2. P. Cohen, Nature Rev. Drug Discov. 1, 309 (2002).
3. D. Fabbro et al., Pharmacol. Ther. 93, 79 (2002).
4. A. Levitzki, Acc. Chem. Res. 36, 462 (2003).
5. D. J. Pratt, J. A. Endicott, M. E. Noble, Curr. Opin. Drug Discov. Dev., in press.
6. D. J. Slamon et al., Science 235, 177 (1987).
7. D. J. Stamon et al., N. Engl. J. Med. 344, 783 (2001).
8. A. J. Barker et al., Bioorg. Med. Chem. Lett. 11, 1911 (2001).
9. M. Hidalgo et al., J. Clin. Oncol. 19, 3267 (2001).
10. J. Baselga, L. A. Hammond, Oncology 63, (Suppl. 1), 6 (2002).
11. A. Wissner et al., Bioorg. Med. Chem. Lett. 12, 2893 (2002).
12. J. Folkman, N. Engl. J. Med. 285, 1182 (1971).
13. F. J. Giles, Oncology (Huntington) 16, 23 (2002).
14. S. S. Sridhar, F. A. Shepherd, Lung Cancer 42 (suppl. 1), S81 (2003).
15. M. Mohammadi et al., Science 276, 955 (1997).
16. C. L. Sawyers, N. Engl. J. Med. 340, 1330 (1999).
17. B. Nagar et al., Cell 112, 859 (2003).
18. B. J. Druker et al., Nature Med. 2, 561 (1996).
19. B. J. Druker, N. B. Lydon, J. Clin. Invest. 105, 3 (2000).
20. M. C. Heinrich et al., Blood 96, 925 (2000).
21. C. D. Blanke, B. L. Eisenberg, M. C. Heinrich, Curr. Treat. Options Oncol. 2, 485 (2001).
22. A. T. Van Oosterom et al., Lancet 358, 1421 (2001).
23. R. Katso et al., Annu. Rev. Cell Dev. Biol. 17, 615 (2001).
24. W. G. McKenna, R. J. Muschel, Genes Chromosomes Cancer 38, 330 (2003).
25. E. H. Walker et al., Mol. Cell 6, 909 (2000).
26. P. T. Lakkakorpi, G. Wesolowski, Z. Zimolo, G. A. Rodan, S. B. Rodan, Exp. Cell Res. 237, 296 (1997).
27. G. Pearson et al., Endocr. Rev. 22, 153 (2001).
28. C. Pargellis et al., Nature Struct. Biol. 9, 268 (2002).
29. P. W. Manley et al., Biochem. Biophys. Acta (2003).
30. L. W. Hardy, A. Malikayil, www.currentdrugdiscovery.com (December 2003), 15 (2003).
31. N. Ono-Saito, I. Niki, H. Hidaka, Pharmacol. Ther. 82, 123 (1999).
32. P. M. Fischer, J. A. Endicott, L. Meijer, in Progress in Cell Cycle Research, L. Meijer, A. Jesequel, M. Rowberger, Eds. (Life in Progress Editions, Roscoff, 2002), vol. 5, pp. 235-248.
33. J. W. Harper, P. D. Adams, Chem. Rev. 101, 2511 (2001).
34. E. A. Sausville, Y. Elsayed, M. Monga, G. Kim, Annu. Rev. Pharmacol. Toxicol. 43, 199 (2003).
35. G. I. Shapiro, J. W. Harper, J. Clin. Invest. 104, 1645 (1999)
36. J. Dancey, E. A. Sausville, Nature Rev. Drug Discov. 2, 296 (2003).
37. G. Kaur et al., J. Natl. Cancer Inst. 84, 1736 (1992).
38. S. Zhai, A. M. Senderowicz, E. A. Sausville, W. D. Figg, Ann. Pharmacother. 36, 905 (2002).
39. S. H. Chao, D. H. Price, J. Biol. Chem. 276, 31793 (2001).
40. Y. Takada, B. B. Aggarwal, J. Biol. Chem. 279, 4750 (2004).
41. A. Kaiser et al., Arch. Biochem. Biophys. 386, 179 (2001).
42. N. G. Oikonomakos et al., J. Biol. Chem. 275, 34566 (2000).
43. W. Tang, G. Eisenbrand, Chinese Drugs of Plant Origin: Pharmacology and Use in Traditional and Modern Medicine (Springer, Heidelberg 1992).
44. Z. Xiao, Y. Hao, B. Liu, L. Qian, Leuk. Lymphoma 43, 1763 (2002).
45. S. Leclerc et al., J. Biol. Chem. 276, 251 (2001).
46. A. M. Senderowicz, E. A. Sausville, J. Natl. Cancer. Inst. 92, 376 (2000).
47. K. S. Kim et al., J. Med. Chem. 45, 3905 (2002).
48. G. Shapiro et al., Proc. Am. Soc. Clin. Oncol. 22, 199 (2003).
49. L. Meijer, E. Raymond, Acc. Chem. Res. 36, 417 (2003).
50. T. Schindler et al., Science 289, 1938 (2000).
51. B. Nagar et al., Cancer Res. 62, 4236 (2002).
52. N. Schiering et al., Proc. Natl. Acad. Sci. U.S.A. 100, 12654 (2003).
53. C. Breitenlechner et al., Structure (Cambridge) 11, 1595 (2003).
54. W. F. De Azevedo, Jr. et al., Proc. Natl. Acad. Sci. U.S.A. 93, 2735 (1996).
55. T. G. Davies et al., Nature Struct. Biol. 9, 745 (2002).
56. L. Tong et al., Nature Struct. Biol. 4, 311 (1997).
57. C. E. Fitzgerald et al., Nature Struct. Biol. 10, 764 (2003).
58. J. Stamos, M. X. Sliwkowski, C. Eigenbrot, J. Biol. Chem. 277, 46265 (2002).
59. L. Shewchuk et al., J. Med. Chem. 43, 133 (2000).
60. B. Zhao et al., J. Biol. Chem. 277, 46609 (2002).
61. L. N. Johnson et al., Pharmacol. Ther. 93, 113 (2002).
62. E. De Moliner, E. D. Lowe, K.-Y. Cheng, L. N. Johnson, unpublished observations; Protein Data Bank ID 1PKD.
63. D. Komander et al., Biochem. J. 375, 255 (2003).
64. R. A. Engh, D. Bossemeyer, Pharmacol. Ther. 93, 99 (2002).
65. H. S. Cho et al., Nature 421, 756 (2003).
66. T. A. Young, B. Delagoutte, J. A. Endrizzi, A. M. Falick, T. Alber, Nature Struct. Biol. 10, 16B (2003).
67. S. Holton et al., Structure (Cambridge) 11, 1329 (2003).
68. G. Kontopidis et al., Structure (Cambridge) 11, 1537 (2003).
69. A. S. Corbin, P. La Rosee, E. P. Stoffregen, B. J. Druker, M. W. Deininger, Blood 101, 4611 (2003).
70. M. E. Gorre et al., Science 293, 876 (2001).
71. M. Azam, R. R. Latek, G. Q. Daley, Cell 112, 831 (2003).
72. L. N. Johnson, M. E. Noble, D. J. Owen, Cell 85, 149 (1996).